BCL2L12: A promising molecular prognostic biomarker in breast cancer
| Autor: | Alexandros Tzovaras, Athina Kladi-Skandali, Kleita Michaelidou, Ioannis Missitzis, George C. Zografos, Alexandros Ardavanis, Andreas Scorilas |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Pathology Clinical Biochemistry Mammary gland Muscle Proteins Breast Neoplasms Kaplan-Meier Estimate Biology Malignancy Disease-Free Survival law.invention Diagnosis Differential Breast cancer law Internal medicine Biomarkers Tumor medicine Humans Polymerase chain reaction Aged Aged 80 and over Univariate analysis Reverse Transcriptase Polymerase Chain Reaction General Medicine Middle Aged Prognosis medicine.disease Gene Expression Regulation Neoplastic medicine.anatomical_structure Real-time polymerase chain reaction Proto-Oncogene Proteins c-bcl-2 Apoptosis Biomarker (medicine) Female |
| Zdroj: | Clinical Biochemistry. 47:257-262 |
| ISSN: | 0009-9120 |
| DOI: | 10.1016/j.clinbiochem.2014.09.008 |
| Popis: | Objectives BCL2-like 12 ( BCL2L12 ) is a new member of the BCL2 gene family that was discovered and cloned by members of our group and found to be expressed in the mammary gland. Many genes of the BCL2 family were found to be implicated in breast carcinogenesis and to serve as possible prognostic markers. The aim of the present study was the quantification of BCL2L12 mRNA expression in order to assess its value as a prognostic tissue biomarker in breast cancer (BC). Design and methods BCL2L12 mRNA levels were determined in a statistically significant sample size of cancerous ( N = 108) and adjacent non-cancerous ( N = 71) breast tissues using a highly sensitive quantitative real-time polymerase chain reaction (qRT-PCR) method. Relative quantification analysis was conducted using the comparative C T (2 − ΔΔ C T ) method, whereas the association between BCL2L12 expression and clinopathological data, disease-free survival (DFS) and overall survival (OS) were estimated by statistical analysis. Results BCL2L12 mRNA expression was decreased in malignant samples compared to the histologically normal counterparts ( p = 0.012). Significant relationships between BCL2L12 expression and TNM stages ( p = 0.009), metastatic potential ( p = 0.012), tumor size ( p = 0.04) and age ( p = 0.024) were observed. Moreover, Kaplan–Meier and Cox univariate analyses indicated that BCL2L12 expression is associated with longer DFS, whereas multivariate analysis pointed out the independent favorable prognostic value of BCL2L12 . Conclusions According to our results, BCL2L12 mRNA expression is a favorable prognostic marker of DFS for BC patients, suggesting its possible application as a novel prognostic indicator of this malignancy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect